Friday, 27 June 2014

First biosimilar insulin to receive CHMP positive opinion in the EU

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union (Lilly)


A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes

These findings are concomitant with a severely decreased insulin-stimulated glucose uptake in muscle, leading to postprandial hyperglycaemia, impaired glucose tolerance and T2D (Nature)

No comments:

Post a Comment